NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44)

The summary for the NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44): The purpose of the NHLBI SBIR Phase IIB Bridge Award is to facilitate and accelerate the capital-intensive steps that are required to transition SBIR/STTR Phase II projects to the commercialization stage by promoting partnerships between SBIR/STTR Phase II awardees and third-party investors and/or strategic partners. Applicants must submit a Commercialization Plan, which should include details on any independent third-party funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NHLBI funds being requested throughout the Phase IIB Bridge Award project period. Projects proposed in response to this FOA must relate to the NHLBI mission and require eventual Federal regulatory approval/clearance. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate, but are not required.
Federal Grant Title: NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-HL-16-009
Type of Funding: Grant
CFDA Numbers: 93.233, 93.837, 93.838, 93.839
CFDA Descriptions: National Center on Sleep Disorders Research; Cardiovascular Diseases Research; Lung Diseases Research; Blood Diseases and Resources Research
Current Application Deadline: Jun 19, 2017
Original Application Deadline: Jun 19, 2017
Posted Date: Feb 25, 2015
Creation Date: Feb 25, 2015
Archive Date: Jul 20, 2017
Total Program Funding:
Maximum Federal Grant Award: $3,000,000
Minimum Federal Grant Award: none
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Small businesses
Additional Information on Eligibility
Other Eligible Applicants include the following:
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-16-009.html
Grant Announcement Contact
NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants
Predoctoral Training in Advanced Data Analytics for Behavioral and Social Sciences Researc...
Cardiovascular Repository Type 1 Diabetes (CARE-T1D) Consortium (U01 Clinical Trial Not Al...
Addressing the Impact of Syndemics on the Health of People with HIV and Diseases and Condi...
Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25...
NHLBI Program Project Applications (P01 Clinical Trials Optional)
Ancillary Studies in Clinical Trials (R01)
Opportunity PA-08-021
Research Demonstration and Dissemination Grants (R18)
More Grants from the National Institutes of Health
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com